Sensorion Archives

News and Trends 6 Jul 2023

Positive data from Sensorion hearing loss study

Sensorion, which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, has reported further analysis from its Proof of Concept (POC) phase 2a clinical trial of SENS-401 for residual hearing preservation in adult patients following cochlear implantation. In June 19, Sensorion announced that in preliminary […]

July 6, 2023 - 3 minutesmins - By Jim Cornall

Best in Biotech 29 Mar 2023

5 hearing loss biotech companies you should know about

More than 1.5 billion people – nearly 20% of the world’s population – live with hearing loss globally, with 430 million suffering from disabling hearing loss. In this article, we take a look at five of the top hearing loss companies making efforts to reduce these figures. According to the World Health Organization (WHO), nearly […]

March 29, 2023 - 7 minutesmins - By Willow Shah-Neville

News and Trends 31 Jan 2023

Sensorion and EVEON collaborating on injection system to deliver gene therapy inner ear treatments

Sensorion and EVEON are collaborating on the design and development of an injection system for the delivery of Sensorion’s gene therapy products to the inner ear. Therapies for treating genetic hearing loss are often challenging due to the need for delivery into the inner ear, a very small and delicate organ embedded in the temporal […]

January 31, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 3 Jan 2023

Sensorion announces first patient enrolled in cisplatin-induced ototoxicity trial

Sensorion has announced that the first patient has been enrolled in its phase 2a proof of concept clinical trial of SENS-401 (Arazasetron) in patients suffering from cisplatin-induced ototoxicity. Cisplatin and other platinum-based compounds are essential chemotherapeutic agents for many cancers. A serious side effect of these therapies is ototoxicity, or permanent and irreversible hearing loss, […]

January 3, 2023 - 3 minutesmins - By Jim Cornall

More News! 30 Nov 2022

FDA grants Sensorion Orphan Drug Designation for hearing loss drug

Sensorion a clinical-stage biotechnology company has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to OTOF-GT, its lead gene therapy program for hearing loss. The drug is intended for the treatment of otoferlin gene mediated hearing loss. Sensorion is on track to file a clinical trial application (CTA) […]

November 30, 2022 - 3 minutesmins - By Liza Laws

More News! 7 Nov 2022

Sensorion granted rare pediatric disease designation by FDA for lead therapy gene

Sensorion has announced that the US Food and Drug Administration (FDA) has granted rare pediatric disease designation to its lead therapy gene candidate, OTOF-GT. The gene therapy is intended for the treatment of otoferlin gene mediated hearing loss. Sensorion’s OTOF-GT gene therapy development program aims to restore hearing in people living with otoferlin deficiency, one […]

November 7, 2022 - 2 minutesmins - By Liza Laws

More News! 24 Oct 2022

Sensorion gets go-ahead from France for trial of drug to prevent hearing loss

Biotech company, Sensorion, today (October 24) announced that the initiation of a proof of concept (PoC) clinical trial of SENS-401 (Arazasetron) in patients with Cisplatin-Induced Ototoxicity (CIO) has been approved by the regulatory authorities in France. Cisplatin and other platinum-based compounds are essential chemotherapeutic agents for many cancers. A serious side effect of these therapies […]

October 24, 2022 - 3 minutesmins - By Liza Laws

News and Trends 12 Sep 2022

Sensorion receives positive opinion from EMA for treatment of hearing loss

The European Medicines Agency (EMA) through its Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion for a treatment for otoferlin gene mediated hearing loss. Clinical-stage biotech, Sensorion, announced the news today (September 12) that its application for an Orphan Drug Designation (ODD) for its lead therapy gene candidate, OTOF-GT will now be […]

September 12, 2022 - 3 minutesmins - By Liza Laws

News and Trends 1 Jul 2022

Progress for hearing preservation trial after Australian approval granted

Approval has been granted by the Australian authorities to allow a French company to progress with a clinical trial testing cochlear implants. Montpellier-based Sensorion will start its proof of concept trial of SENS-401, a drug candidate that aims to protect and preserve inner ear tissue from damage. Sensorion is a biotech company specializing in the […]

July 1, 2022 - 3 minutesmins - By Liza Laws

News and Trends 16 Mar 2020

Coronavirus Delays Sensorion’s Hearing Loss Phase II Trial

The French company Sensorion has been forced to delay a phase II trial in people with hearing loss due to slow patient recruitment amid the current coronavirus disease (Covid-19) pandemic. The clinical trial is designed to test Sensorion’s lead candidate drug in people with sudden sensorineural hearing loss, a rare disorder where the patient can […]

March 16, 2020 - 2 minutesmins - By Jonathan Smith

More News! 3 Dec 2019

Sensorion’s Vertigo Drug Abandoned in Phase II

A small molecule drug developed by the French company Sensorion has proven ineffective in a phase IIb trial for the treatment of a rare vertigo condition, leading the company to close down the development of the drug. The phase IIb trial tested Sensorion’s lead drug in 105 patients with the rare condition acute unilateral vestibulopathy, […]

December 3, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 14 Jun 2019

French Biotech Raises €20M to Prevent Hearing Loss

The hearing loss biotech Sensorion has issued bonds to raise €20M, which it will use to fund the phase II development for first-in-class drugs treating hearing loss and severe vertigo. The money will pay for phase II trials of Sensorion’s two most advanced treatments, which are small molecule drugs to treat sudden deafness and acute […]

June 14, 2019 - 2 minutesmins - By Jonathan Smith

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Sensorion

Positive data from Sensorion hearing loss study

5 hearing loss biotech companies you should know about

Sensorion and EVEON collaborating on injection system to deliver gene therapy inner ear treatments

Sensorion announces first patient enrolled in cisplatin-induced ototoxicity trial

FDA grants Sensorion Orphan Drug Designation for hearing loss drug

Sensorion granted rare pediatric disease designation by FDA for lead therapy gene

Sensorion gets go-ahead from France for trial of drug to prevent hearing loss

Sensorion receives positive opinion from EMA for treatment of hearing loss

Progress for hearing preservation trial after Australian approval granted

Coronavirus Delays Sensorion’s Hearing Loss Phase II Trial

Sensorion’s Vertigo Drug Abandoned in Phase II

French Biotech Raises €20M to Prevent Hearing Loss

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!